Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Systemic Lupus Erythematosus

Launched by HEBEI MEDICAL UNIVERSITY · Jul 13, 2017

Keywords

ClinConnect Summary

To ensure that all patients of systemic lupus erythematosus (SLE) completed 6-months follow-up, twenty SLE patients ranging from 14 to 60 years old were enrolled in this trial. Participants matched with the inclusion criteria were allocated randomly into two groups:Human Umbilical Cord Derived Mesenchymal Stem Cells (hUC-MSCs) treated group and control group. Clinical trials are being increasingly established to investigate the therapeutic potential of these cells for SLE. The aim of the present study is to investigate safety and efficacy of vein infusion of allogeneic hUC-MSCs in patients ...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Diagnosis of SLE(Systemic lupus erythematosus) from American College of Rheumatology(ACR) according to established criteria in 1997
• • 2. Age from 14 to 60 years
• • 3. No serious infection or acute hemorrhage
• • 4. Left ventricular ejection fraction (LVEF)≥ 50%
• • 5. Both transaminase and serum creatinine level are more than twice times the upper limit of normal
• • 6. No acute infectious diseases.
• • 7. Understanding and willingness to sign a written informed consent document.
• Exclusion Criteria:
• Patients with SLE have to be disqualified from this study if any of the following is applicable:
• • 1. SLE(Systemic lupus erythematosus) with severe infection.
• • 2. Severe heart attack, liver and kidney disease following serious complications
• • 3. Patients with allergic constitution.
• • 4. Pregnancy and breastfeeding women.
• • 5. Accompanied by malignant tumors or other malignant disease
• • 6. Patients as participant in the other clinical text
• • 7. Patients with active tuberculosis, acute sever hepatitis or infectious period of diseases.